Orbit Discovery

Orbit develop and apply innovative drug discovery platforms defined by a unique peptide display engine that deliver novel, functional, biologically relevant peptide therapeutic leads. The Orbit peptide display engine is uniquely able to address cell-based targets and thereby screen targets in relevant contexts. Peptide leads are key starting points for the development of peptide, peptidomimetic and small molecule therapeutics as well as bioconjugates for cell targeting and cargo delivery. Founded in late 2015 as a spin-out from Oxford University based on the work of Professors Graham Ogg and Terry Rabbitts. We have a pipeline of novel targets in in-house programmes...

Peptide display,non-natural amino acids,cell-surface targets,transcription,translation,transcription/translation on bead,drug discovery,constrained peptides,and peptide drugs

Orbit discovery operates in the Biotechnology research industry.

Orbit discovery's revenue is 1m - 10m

Orbit discovery has 11 - 50 employees.